Author

R. Somwar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. Ladanyi· 4 shared A. Liu· 2 shared D. Lu· 2 shared E. De Stanchina· 2 shared F. D. Johnson· 2 shared G. de Rappard-Yuswack· 2 shared R. Shi· 2 shared W. Lockwood· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

M. Ladanyi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

bioRxiv · Feb 6, 2023Cancer Biology

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression

D. A. Farnsworth, Y. Inoue, F. D. Johnson, G. de Rappard-Yuswack, D. Lu, R. Shi, R. Somwar, M. Ladanyi, A. M. Unni, W. Lockwood

The paper identifies drug addiction to MEK inhibitors in KRAS-mutant lung cancer cells, showing that resistance is linked to ERK suppression and KRAS amplification, suggesting therapeutic strategies involving drug holidays.

bioRxiv · Apr 29, 2022 · PreprintCancer Biology

A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1

F. D. Johnson, J. Ferrarone, A. Liu, C. Brandstadter, R. Munuganti, D. Fansworth, D. Lu, J. Luu, T. Sihota, S. Jansen, A. Nagelberg, R. Shi, G. C. Forcina, X. Zhang, G. S. W. Cheng, , W. W. Lockwood

The paper identifies LCS3, a compound that induces oxidative stress in lung cancer cells by inhibiting disulfide reductases GSR and TXNRD1, and shows its synergistic effect with glutathione and thioredoxin pathway inhibition.

bioRxiv · Jun 28, 2021 · PreprintCancer Biology

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Y. Inoue, A. Nikolic, D. Farnsworth, A. Liu, M. Ladanyi, R. Somwar, M. Gallo, W. Lockwood

This study identifies the ERK-CBP/p300-ETS axis as promoting lineage transformation between neuroendocrine and non-neuroendocrine lung cancer subtypes through chromatin rewiring.

bioRxiv · Nov 12, 2020Cancer Biology

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

R. S. Smith, I. Odintsov, Z. Liu, T. Hayashi, A. J. W. Lui, M. Vojnic, Y. Suehara, M. S. Mattar, J. Hmeljak, H. A. Ramirez, M. Shaw, G. Bui, A. B. Hartono, E. Gladstone, H. Magnan, , R. Somwar

This study develops new DSRCT models and shows that targeting the ERBB pathway with EGFR inhibitors reduces tumor growth in preclinical models.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology